What does it mean when a skin biopsy is misreported in Ireland?

A misreported skin biopsy means the laboratory had the cancer in front of it and recorded the wrong answer. The lesion was removed, the tissue reached the laboratory, and a consultant histopathologist examined it. Yet the report described a benign mole, rather than the melanoma or other skin cancer that was present. Understanding whether this happened is the first step toward knowing whether you can pursue compensation for injury in Ireland.

This is a deliberately narrow topic, and the distinction matters for your claim. It is different from a missed melanoma claim, where a GP or specialist fails to recognise or refer a suspicious mole in the first place. For that situation, see our page on melanoma and skin cancer misdiagnosis. It is also narrower than the general mechanism page on a misread scan, biopsy or histopathology across all cancer types. Here the assumption is fixed: a biopsy was performed, and the report on it was wrong.

The same failure can affect any skin cancer, not only melanoma. Melanoma is the focus of this page because it is the most aggressive and the most consequential to misread. Basal cell carcinoma and squamous cell carcinoma are also diagnosed only by examining tissue under a microscope. A squamous cell carcinoma reported as a benign or low-grade lesion, or an invasive cancer reported as a harmless growth, follows the same legal pattern as a misreported melanoma. The principles on this page apply to all of them, even though the clinical detail and the prognosis differ by cancer type.

Diagnosis of melanoma does not come from looking at the skin. It depends entirely on the microscopic examination of tissue by a pathologist. That is why a reporting error is so consequential. A patient who is told a lesion is benign is reassured, discharged, and sent back to ordinary life, while an untreated cancer continues to grow. Ireland recognises this risk directly: the National Histopathology Quality Improvement Programme exists to catch exactly this kind of reporting error before it reaches the patient^[15].

What are the signs a skin biopsy may have been misreported?

The clearest warning sign is a cancer that appears where a lesion was already biopsied and called benign. A misreported biopsy is usually discovered later, not at the time, because the wrong result is reassuring. Certain patterns are worth taking seriously, and none of them is a diagnosis in itself. They are reasons to ask for the original slides to be reviewed.

The common patterns include a melanoma or other skin cancer later diagnosed at or near the site of an earlier "benign" biopsy. A lump, a spreading patch, or a new lesion appearing in the months or years after a reassuring result is another. So is a lesion that was removed, reported as benign, yet kept changing, growing or bleeding afterwards. A later hospital review, audit or open disclosure that mentions the original sample is the most direct signal of all. Any of these is a reason to seek advice, because the original tissue still exists and can be re-examined.

How does a skin biopsy get reported as benign when melanoma is present?

These failures are almost always human interpretive errors, not machine faults, and they fall into a small number of recognised patterns. The tissue is fixed, set in paraffin wax, sliced thinly, mounted on glass and stained, then read down a microscope. The errors that found legal claims happen during that reading and reporting.

A malignant lesion reported as completely benign

The most serious pattern. A melanoma is recorded as a benign mole, such as a benign melanocytic naevus, and the patient is discharged with no follow-up.

The cancer is identified but the depth is under-reported

The pathologist confirms melanoma but understates the Breslow thickness, the measurement that dictates surgical margins and staging. An understated depth can deprive a patient of the wider surgery or sentinel node biopsy they needed.

Important features are left out of the report

The Royal College of Physicians of Ireland Faculty of Pathology sets the elements a melanoma report must record. These include the Breslow thickness, the mitotic rate, ulceration, microsatellites and regression. This dataset is what makes the standard measurable, because a report that omits a required element can be tested against a published benchmark. Omitting these features can also change the treatment that follows.

Sampling error rather than reading error

A punch biopsy takes only part of the lesion and can miss a deeper invasive component. Whether the failure was in taking a representative sample or in reading it is itself part of the analysis, and an independent expert distinguishes the two.

Why some melanomas are misread more often

Some melanomas are genuinely harder to read, and this clinical background is part of what a court weighs. It does not excuse a clear error, but it explains why expert evidence rather than hindsight decides these cases.

Three subtypes cause particular difficulty. Nodular melanoma grows vertically and quickly, so it can lack the classic surface features pathologists and clinicians look for. Amelanotic melanoma carries little or no dark pigment and can resemble a harmless inflammatory patch or a benign growth. Acral and subungual melanomas appear on the palms, the soles or under a nail, where they are sometimes mistaken for a bruise, a wart or a fungal problem. A lesion in one of these categories raises the stakes on the reporting step, because the safety margin for a confident benign call is smaller.

What the words on a skin biopsy report mean

The language on a histopathology report can hide how uncertain a reading was, so a few terms are worth knowing. A "naevus" is the medical word for a mole, and "benign melanocytic naevus" means the pathologist judged it a harmless mole. The word "melanoma" means a cancer of the pigment cells was found. "Breslow thickness" is the depth of the cancer in millimetres, and it is the single most important figure on the report, because it drives staging and treatment.

Some words signal that the reading was not clear-cut. "Atypical" or "dysplastic" means the cells were unusual but not clearly cancer. Phrases such as "suspicious for", "cannot exclude" or "favour benign" mean the pathologist was not certain. A report carrying any of these terms, followed by no further action, is a reasonable trigger for an independent review. Uncertainty on the page is exactly where a missed melanoma can hide.

Why is a misread biopsy a recognised failure point in Ireland?

Ireland built a national system to catch exactly this kind of error, which is strong evidence that the risk is real and that a safety net is expected to operate. The National Quality Improvement Programme in Histopathology was launched in January 2009. The Faculty of Pathology records that it was set up "as a matter of priority following high-profile cancer misdiagnosis cases in Ireland"^[14]. It has been funded by the Health Service Executive since 2014. It now collects quality data from every public histopathology laboratory and a number of private laboratories, through a central system known as NQAIS^[14].

The most important safeguard is the second read. When a case is discussed at a multidisciplinary team meeting, a second pathologist effectively reviews the first pathologist's conclusion. A national study of more than 1.4 million histopathology and cytopathology cases over five years measured what that second read achieves^[13]. Cases reviewed at these meetings had a revised-report rate of 1.25 per cent, compared with 0.16 per cent for cases that were not reviewed. In other words, a case that received a second specialist's eyes was around eight times more likely to have its report corrected before treatment began^[13].

The programme also sets measurable targets that describe what competent practice looks like. These include a national diagnostic concordance target of 97 per cent and a peer-review agreement target of at least 95 per cent^[14]. These figures matter legally as well as clinically. They establish that careful re-checking of difficult specimens is the expected standard, which is the backdrop against which a single uncorrected misread is judged.

What the evidence shows about second reads

International evidence shows why melanoma is singled out for this scrutiny. Studies of melanocytic lesions, the family that includes melanoma, report that diagnostic agreement between pathologists can be poor. A second specialist review changes the reading in a meaningful share of cases. One melanoma referral centre found a discordance rate of 14.3 per cent between the original report and expert review^[19]. A larger European study found disagreement in just over a third of referred cases, and in two thirds of those the change was significant enough to alter treatment^[20]. This does not mean every disagreement is negligent. It means the second read is not a formality, and the absence of one is exactly when a clear error survives uncorrected.

Has an Irish court dealt with a misreported skin biopsy?

Yes, and one reported settlement shows exactly how serious this failure can be. In July 2022 the High Court approved a €2 million settlement for a teenage boy whose melanoma had been reported as benign^[17]. The case is reported here to illustrate how these claims resolve in Ireland. It is not a prediction of any outcome, and every claim depends on its own facts.

The sequence is the pattern this page describes. In 2018 the boy had a lesion removed at the National Children's Hospital in Tallaght, and the sample was sent to Children's Health Ireland at Crumlin for analysis^[18]. Because it was reported as benign, the melanoma went undiagnosed for more than two years, and he was discharged without follow-up. The cancer was only found when he returned with a lump on his neck that proved to be metastatic melanoma^[17].

Liability was admitted, so the court dealt only with the amount of compensation. The hospitals read an apology into the record, confirming that mistakes had been made in the boy's diagnosis and treatment. Mr Justice Paul Coffey approved the settlement as fair and reasonable^[18]. The figure reflects the harm in that particular case. It is not a guide to what any other claim is worth, because awards are assessed case by case under the Personal Injuries Guidelines^[10].

How do we prove a skin biopsy was misreported?

The case is built on the original tissue, re-examined by an independent expert, and then measured against the Dunne standard. Because the cancer was physically sampled, the proof is unusually tangible. The glass slides and the paraffin blocks still exist, and laboratories in Ireland retain them for a minimum of ten years. Your solicitor secures them through a medical records request or a formal notice. They are then sent to an independent consultant histopathologist for a blinded review, meaning the expert reads the tissue without seeing the original report.

If that independent review concludes that the slide clearly showed melanoma, or that the Breslow depth was significantly understated, you have the foundation of a breach of duty. The legal test is Dunne v National Maternity Hospital^[1]. The question is whether no reasonably competent consultant histopathologist of equal status, exercising ordinary care, would have made the same reading. The law does not demand perfection, and competent specialists can genuinely disagree about a borderline lesion. A clear reading error below the expected standard is a different matter, and it is provable.

The Irish courts apply Dunne and nothing else to laboratory diagnosis. The Supreme Court confirmed this in Morrissey v Health Service Executive, declining to import a different "absolute confidence" test^[2]. It held that the Dunne principles remain the exclusive standard for all clinical negligence, including diagnostic laboratory work. Clinical guidelines inform that standard but do not replace it, as the High Court reaffirmed in Perez v Coombe^[3].

This is where Irish law differs from English law, a distinction that matters because much online guidance is written for the United Kingdom. England and Wales apply the Bolam test, which asks whether a responsible body of medical opinion would support the practice. The Irish Dunne test is framed differently, asking whether no competent practitioner of equal status would have made the error. Information based on the NHS, on English time limits, or on Bolam does not state the law that applies to a misreported biopsy in Ireland.

What records prove a misreported biopsy

A pathology claim turns on laboratory material more than on clinical notes, so the records that matter are specific. Your solicitor secures three things, and the laboratory must retain the physical material for at least ten years. The first is the original glass slides, the exact tissue sections the first pathologist examined, which let an independent expert review the same material and identify what was missed. The second is the paraffin tissue blocks, the preserved tissue from which new slides can be cut and modern stains applied that may not have been used the first time. The third is the laboratory's report and dispatch records, which show what was reported, when, and to whom it was sent. Those dispatch records matter because they separate a reporting failure inside the laboratory from a later failure to act on the result.

How does a false benign report cause harm?

A reporting error that lets a melanoma grow undetected can turn a highly curable cancer into an advanced one, and that change in prognosis is the legal harm. In Irish law it is not enough to show the pathologist made a mistake. You must show the mistake caused a worse outcome or more invasive treatment than a correct report would have required. For melanoma, the measure that proves this is Breslow thickness, the depth of the tumour in millimetres.

The relationship between depth and survival is steep, and it is what makes a delay so damaging. Breslow thickness drives both the stage of the cancer and the treatment it needs. The table below shows the pattern in general terms, drawn from melanoma staging guidance^[15]. It describes typical figures, not a prediction for any individual, because every case turns on its own facts.

The legal significance is direct. A melanoma caught at or below 0.8 mm is highly survivable and usually needs only minor surgery. The same tumour, left to grow past 4 mm because a biopsy was reported as benign, can demand disfiguring surgery and systemic treatment, with a far worse outlook. Our page on reduced life expectancy explains how that loss is approached.

Why a preserved slide is strong evidence of causation

This is also where a misreported biopsy is, in evidential terms, often a stronger case than a missed mole. In Crumlish v Health Service Executive, a delayed breast cancer claim failed at the first causation hurdle^[4]. The only evidence the tumour existed at the earlier date was a contested mathematical model of tumour growth, and once that was rejected the claim collapsed. A misreported biopsy avoids that trap. The tissue was physically taken and preserved, so a re-read of the original slide can show the cancer was present and reportable at the time of the error.

Irish law also recognises the loss of a chance of earlier and less drastic treatment as a compensable injury, following Philp v Ryan^[6]. That doctrine sits in some tension with later authority and is not fully settled^[5]. Our page on loss of chance in cancer claims sets out where that line currently rests.

What can a claim for a misreported biopsy include?

Compensation reflects the additional harm the delay caused, which in skin cancer cases is often considerable. Because the melanoma was allowed to progress, the surgery finally required is frequently far more extensive than the simple excision that an early diagnosis would have needed. General damages in Ireland are assessed under the Personal Injuries Guidelines^[10]. They can reflect significant or disfiguring scarring from wider excision or skin grafts. They can also reflect any psychiatric injury arising from an avoidable advanced diagnosis after false reassurance.

Special damages, which cover financial losses, are not capped and are often the larger part of a serious claim. They can include the cost of more intensive treatment and ongoing surveillance, lost earnings, and future care. A proposed second edition of the Guidelines would raise the general damages brackets by about 16.7 per cent, but that has not been enacted into law, so current brackets apply^[10]. Our cancer misdiagnosis compensation page explains how these elements are valued. We do not use compensation calculators, because no honest figure can be given without your specific medical evidence.

How long do I have to claim for a misreported skin biopsy?

The time limit is two years less one day, but it usually runs from when you learned the report was wrong, not from the date of the biopsy. This is the most important point for anyone who was told years ago that a lesion was benign. The two-year period is set by section 7 of the Civil Liability and Courts Act 2004, and the clock starts on your date of knowledge, a concept defined in the Statute of Limitations (Amendment) Act 1991^[9]. That is the date you first knew, or ought reasonably to have known, four things. They are that you were injured, that the injury was significant, that it was attributable to the act or omission complained of, and who was responsible.

In a misreported biopsy case these dates are often years apart. The harm is hidden by the very report that was wrong. The patient is reassured, and the cancer is only revealed later when it returns or spreads and the original slide is re-examined. The Supreme Court has confirmed that a cause of action of this kind runs from when the damage is capable of being discovered^[7].

The date-of-knowledge regime exists precisely to protect people whose injuries were not immediately apparent^[8]. The Act also states that knowing whether the events legally amounted to negligence is not part of the test^[9]. So being reassured that a result was "benign" does not start or forfeit your time.

Different rules apply to children. Where the patient was under 18 at the time, the two-year period generally does not begin until their 18th birthday.

Who is liable, and does the hospital have to tell me?

The claim can lie against the laboratory, the hospital, or the Health Service Executive, and outsourcing the analysis does not remove responsibility. Skin biopsies are often analysed by a laboratory that is separate from the clinic or hospital where the lesion was removed. A claim can be brought against the laboratory responsible for the analytical error directly, and an expert report must address the conduct of each defendant named^[4].

The position of the Health Service Executive is important. In Morrissey, the Supreme Court drew a careful line. While the HSE was not vicariously liable for the independent acts of a third-party laboratory, it owed a non-delegable duty to patients using its service^[2]. In plain terms, the HSE cannot escape responsibility simply by sending the analysis to an outside contractor. It remains accountable for the safe delivery of the diagnostic service.

There is also a duty of candour. Under the Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023, which commenced on 26 September 2024, healthcare providers must openly disclose a defined list of serious patient safety incidents, set out in Schedule 1 to the Act^[11]. That list is mostly confined to unanticipated deaths and specified maternity and neonatal events, so the mandatory duty will not attach to every misreported biopsy; whether a particular case falls within it depends on the facts. Where it does apply, the provider must inform the patient, explain what happened and apologise. Separately, the Act gives patients a right to request a review of a CervicalCheck, BreastCheck or BowelScreen screening result, though that right concerns those screening programmes rather than an individual histopathology biopsy. An apology made during open disclosure cannot be used against the provider as an admission of liability^[11].

The records that prove what happened carry decisive weight. They include the slides, the blocks and the laboratory's reporting logs, and the courts favour contemporaneous records over later recollection^[16].

What should you do if you think your biopsy was misreported?

The most useful first step is to preserve the evidence, because the original tissue is what proves or disproves an error. You do not need to have decided about a claim to do this. The steps below protect your position while you find out where you stand, and time matters because the limitation clock runs from your date of knowledge.

Start by requesting a full copy of your medical records, including the original histopathology report. Ask, in writing, that the original glass slides and paraffin blocks are retained and not destroyed, since laboratories keep them for at least ten years but you want them safe. Arrange for an independent consultant histopathologist to carry out a blinded review of that tissue, which a medical negligence solicitor can organise. Take legal advice on your time limit early. The two-year period turns on when you knew or ought to have known of the error, and that date is specific to your circumstances.

How we can help

If you were told a skin lesion was benign and later learned it was a melanoma, you may be anxious about whether anything went wrong. You may also fear it is too late to ask. We can help you find out. As personal injury solicitors in Dublin acting for clients across Ireland, we obtain your records and the original slides. We instruct an independent consultant histopathologist to carry out a blinded review. We then assess both whether the original report fell below the required standard and whether the delay changed your prognosis.

Related guides: melanoma and skin cancer misdiagnosis · misread scan, biopsy or histopathology · pathology and laboratory errors · cancer misdiagnosis claims · date of knowledge and time limits